Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer

Cath Eberlein,Stuart C. Williamson,Lorna Hopcroft,Susana Ros,Jennifer I. Moss,James Kerr,Wytske M. van Weerden,Elza C. de Bruin,Shanade Dunn,Brandon Willis,Sarah J. Ross,Claire Rooney,Simon T. Barry

DOI: https://doi.org/10.1038/s41416-024-02614-w

IF: 9.075

2024-02-25

British Journal of Cancer

Abstract:To explore the anti-tumour activity of combining AKT inhibition and docetaxel in PTEN protein null and WT prostate tumours.

oncology